SUZHOU, China, March 26, 2026 /PRNewswire/ — Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced its annual results for the year ended December 31, 2025 on March 25, 2026….
Other News
Cleerly to Debut Cleerly PREVIEW and Showcase New AI-QCT Research at ACC.26
DENVER–(BUSINESS WIRE)– #AI–Cleerly, a leader in advanced cardiovascular imaging analysis, will be attending the 75th Annual Scientific Session & Expo of the American College of Cardiology (ACC.26). The conference will take place March 28–30, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. ACC.26 convenes clinicians, researchers, and innovators from around the world to advance the science and practice of heart care. Cleerly will mark the conference with the launch of
HeartSciences’ MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category
Southlake, TX , March 25, 2026 (GLOBE NEWSWIRE) — HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that its MyoVista Insights™ platform has received Epic Toolbox designation for the ECG Management System category.
AISAP and Cardiology Consultants of Philadelphia (CCP) Launch Strategic Partnership to Combat Heart Failure and Valvular Disease Through Advanced AI Cardiac Platform
The partnership will provide America’s largest independent cardiovascular practice with access to AISAP’s AI-enabled cardiac diagnostic platform NEW YORK and PHILADELPHIA, March 25, 2026 /PRNewswire/ — AISAP, a pioneer in AI-powered medical diagnostics, and Cardiology Consultants of…
Philips launches IntraSight Plus to simplify coronary interventions and advance precision care
March 25, 2026
CorVista Health to Present New Data on Non-Invasive Point of Care Test for Ischemia with Non-Obstructive Coronary Arteries Using Machine Learning at ACC.26
BETHESDA, Md.–(BUSINESS WIRE)–CorVista Health today announced the upcoming poster presentation of new data on its non-invasive point of care test for ischemia with non-obstructive coronary arteries (INOCA) – a common condition, particularly in women, where patients experience cardiovascular symptoms despite having no flow-limiting blockages in their major epicardial arteries – using machine learning at the American College of Cardiology’s Annual Scientific Session (ACC.26), taking place March
Microbot Medical® Strengthens LIBERTY® Endovascular Robotic System Position with Publication of its ACCESS PVI Pivotal Study in Leading Peer-Reviewed Medical Journal
Microbot Medical® Strengthens LIBERTY®’s Position with Publication of its ACCESS PVI Pivotal Study in Leading Peer-Reviewed Medical Journal
Adagio Medical Announces Publication of Pre-Clinical Results for Next Generation Ventricular Ablation Catheter
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the publication of pre-clinical results of the Company’s next generation ultra-low temperature ablation (“ULTA”) technology designed to treat ventricular arrhythmias. The publication, which is titled “Initial Pre‐Clinical Evaluation of the Augmented Ultra‐Low Temperature Cr
Clarius Unveils T-Mode™ Heart: New AI-Powered Training Tool Empowers Primary Care Physicians to Perform Cardiac Ultrasound Exams
By simplifying complex cardiac anatomy through real-time AI labeling, T-Mode™ Heart removes the training barrier to ultrasound adoption for family physicians and medical students. VANCOUVER, BC, March 23, 2026 /PRNewswire/ — With cardiovascular disease remaining a leading cause of death…
Three New Studies Show Viz.ai’s Cardio Suite Speeds Detection of Cardiac Disease and Improves Patient Follow-Up
SAN FRANCISCO–(BUSINESS WIRE)– #ai–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that three abstracts featuring Viz HCM, the company’s AI-powered ECG analysis and care coordination solution designed to detect and triage patients with signs of hypertrophic cardiomyopathy (HCM), part of the Viz Cardio Suite, have been accepted for presentation at the American College of Cardiology’s Annual Scientific Session (ACC.26), taking place March 28–30,



